Veracyte, Inc.
corporate_fare Company Profile
Veracyte, Inc. (NASDAQ:VCYT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 18 items for VCYT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-23, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for VCYT spans 8-K, 10-Q, DEF 14A, 10-K.
Recent high-impact activity:
- Decipher Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer, STAMPEDE Data Show
- Medicare Covers Veracyte's Prosigna Breast Cancer Test, Opening U.S. Reimbursement
- Decipher Test Predicts Hormone Therapy Benefit in Prostate Cancer Trial
- Veracyte Closes $150M Acquisition of Convergent Genomics, Bolstering UroAmp Bladder Cancer Platform
- Veracyte Buys Convergent Genomics to Add Urinary Tumor DNA Testing
Financial Snapshot
Short Interest & Short Volume
8.50 days to coverFINRA reported short interest of 9,821,453 shares in VCYT as of the October 15, 2026 settlement, a 3.5% decrease from the prior period — about 8.5 days to cover at its recent average daily volume. On November 2, 2026, 60.1% of VCYT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.